Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 86,936 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 86,936 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $1.43, for a total transaction of $124,318.48. Following the completion of the transaction, the insider directly owned 6,355,717 shares of the company’s stock, valued at approximately $9,088,675.31. The trade was a 1.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $1.31 on Tuesday. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.52. The company has a 50 day moving average of $1.62 and a 200 day moving average of $1.32. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $59.91 million, a P/E ratio of -0.80 and a beta of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Quadrature Capital Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $28,000. Vontobel Holding Ltd. purchased a new stake in Werewolf Therapeutics in the 1st quarter valued at $34,000. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter valued at $48,000. Nuveen LLC purchased a new stake in Werewolf Therapeutics in the 1st quarter valued at $71,000. Finally, AQR Capital Management LLC purchased a new stake in Werewolf Therapeutics in the 1st quarter valued at $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

HOWL has been the subject of a number of recent research reports. Bank of America decreased their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. JMP Securities reduced their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Finally, Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.